Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models

被引：6
|
作者：
Borodovsky, Alexandra [1 ]
Wang, Yanjun [1 ]
Ye, Minwei [1 ]
Shaw, Joseph C. [1 ]
Sachsenmeier, Kris [1 ]
Deng, Nanhua [1 ]
Goodwin, Kelly [1 ]
Clarke, James D. [1 ]
Goodwin, Richard [1 ]
Strittmatter, Nicole [1 ]
Hay, Carl [2 ]
Sah, Vasu [1 ]
Deborah, Lawson [1 ]
Reimer, Corinne [1 ]
Congreve, Miles [3 ]
Mason, Jonathan [3 ]
Marshall, Fiona [3 ]
Lyne, Paul [1 ]
Woessner, Richard [1 ]
机构：
[1] AstraZeneca, Boston, MA USA
[2] MedImmune, Gaithersburg, MD USA
[3] Heptares Therapeut, Welwyn Garden City, Herts, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3751
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
    Wullschleger, Stephan
    Tichet, Melanie
    Codarri-Deak, Laura
    Umana, Pablo
    Klein, Christian
    Hanahan, Douglas
    CANCER RESEARCH, 2021, 81 (13)
  • [42] Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma
    Hsu, Fei-Ting
    Liu, Yu-Chang
    Tsai, Chang-Liang
    Yueh, Po-Fu
    Chang, Chih-Hsien
    Lan, Keng-Li
    CANCERS, 2021, 13 (08)
  • [43] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, M.
    Guo, W.
    Xu, Q.
    Sun, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1856 - 1856
  • [44] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, Mingxia
    Guo, Wenjie
    Wu, Yuanyuan
    Yang, Chenxi
    Zhong, Liang
    Deng, Guoliang
    Zhu, Yuyu
    Liu, Wen
    Gu, Yanhong
    Lu, Yin
    Kong, Lingdong
    Meng, Xiangbao
    Xu, Qiang
    Sun, Yang
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (02) : 304 - 315
  • [45] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Mingxia Zhao
    Wenjie Guo
    Yuanyuan Wu
    Chenxi Yang
    Liang Zhong
    Guoliang Deng
    Yuyu Zhu
    Wen Liu
    Yanhong Gu
    Yin Lu
    Lingdong Kong
    Xiangbao Meng
    Qiang Xu
    Yang Sun
    ActaPharmaceuticaSinicaB, 2019, 9 (02) : 304 - 315
  • [46] Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host
    Mony, Jyothi
    Zhang, Lixin
    Tirodkar, Tejas
    Elishaev, Esther
    Brozick, Joan
    Edwards, Robert P.
    Vlad, Anda M.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [47] MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models.
    Faia, Kerrie
    Toso, Alberto
    Fetalvero, Kristina
    Roche, Marly
    Bench, Steven
    O'Hearn, Erin
    Cao, Qiongfang
    Bright, Kerry-Ann
    Paduraru, Debora
    Romagnani, Andrea
    Weng, Weifan
    Zimmermann, Tina
    Burke, Michael
    Close, Joshua
    Green, Luke
    Kim, Joseph
    Miduturu, Chandra
    Ribeiro, Alison
    Bacac, Marina
    Herter, Sylvia
    Perola, Emanuele
    Sheets, Michael
    Eckmann, Jan
    Heidkamp, Gordon
    Traore, Tary
    Gerson, Erik
    Woessner, Rich
    Wolter, Carsten
    Scheuplein, Felix
    Perez, Nisha
    LaBranche, Timothy
    Silva, Grace
    Ye, Chaoyang
    Utt, Caitlin
    Gross, Stefan
    Bischoff, James R.
    Dorsch, Marion
    Guzi, Tim
    Hoeflich, Klaus
    Brubaker, Jason
    CANCER RESEARCH, 2021, 81 (13)
  • [48] Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
    Xu, Chunxiao
    Zhang, Yanping
    Rolfe, P. Alexander
    Hernandez, Vivian M.
    Guzman, Wilson
    Kradjian, Giorgio
    Marelli, Bo
    Qin, Guozhong
    Qi, Jin
    Wang, Hong
    Yu, Huakui
    Tighe, Robert
    Lo, Kin-Ming
    English, Jessie M.
    Radvanyi, Laszlo
    Lan, Yan
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5869 - 5880
  • [49] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
    Allen, Elizabeth
    Jabouille, Arnaud
    Rivera, Lee B.
    Lodewijckx, Inge
    Missiaen, Rindert
    Steri, Veronica
    Feyen, Kevin
    Tawney, Jaime
    Hanahan, Douglas
    Michael, Iacovos P.
    Bergers, Gabriele
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
  • [50] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo (vol 11, 5774, 2021)
    Li, Maohua
    Zhao, Rongqing
    Chen, Jianxin
    Tian, Wenzhi
    Xia, Chenxi
    Liu, Xudong
    Li, Yingzi
    Li, Song
    Sun, Hunter
    Shen, Tong
    Ren, Wenlin
    Sun, Le
    SCIENTIFIC REPORTS, 2022, 12 (01)
12345